Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy

Bone

Volumn 55, Issue 1, 2013, Pages 113-118

  Allison, M B ^a   Markman, L ^a   Rosenberg, Z ^a   Vieira, R L ^a   Babb, J ^a   Tejwani, N ^a   Peck, V ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atypical; Bisphosphonate; Fracture

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; ATYPICAL INCOMPLETE FEMUR SUBTROCHANTERIC FRACTURE; BONE DENSITY; BONE MARROW EDEMA; BONE RADIOGRAPHY; CORTICAL THICKNESS (BONE); DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FEMUR SUBTROCHANTERIC FRACTURE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; PATIENT COMPLIANCE; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FEMUR; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84877065670     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.03.018     Document Type: Article

References (29)

1. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
2. Drake M.T., Clarke B.L., Khosla S. Bisphosphonate: mechanisms of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
3. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
4. Abrahamsen B., Eiken P., Eastell R. Subtronchanteric and diaphyseal femur fractures in patient treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
5. Ali T., Jay R.H. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing 2009, 38:625-626.
6. Armamento-Villareal R., Napoli N., Diemer K., Watkins M., Civitelli R., Teitelbaum S., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85:37-44.
7. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556-2561.
8. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010, 468:1991-1996.
9. Edwards M.H., McCrae F.C., Young-Min S.A. Alendronate-related femoral diaphysis fracture - what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporos Int 2010, 21:701-703.
10. Goddard M.S., Reid K.R., Johnston J.C., Khanuja H.S. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009, 32:8.
11. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349-353.
12. Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775-785.
13. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
14. Lee P., Seibel M.J. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359:317-318.
15. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
16. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
17. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
18. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009, 72:161-168.
19. Sayed-Noor A.S., Sjoden G.O. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report. Acta Orthop 2008, 79:565-567.
20. Sayed-Noor A.S., Sjoden G.O. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009, 467:1921-1926.
21. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009, 80:413-415.
22. Schneider J.P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009, 64:18-23.
23. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
24. Tucci J.R. Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients. J Endocrinol Invest 2008, 31:251-254.
25. Mashiba T., Mori S., Burr D.B., Komatsubara S., Cao Y., Manabe T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005, 23:36-42. [Suppl.].
26. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 2:169-180.
27. Dell R., Greene D., Ott S. A retrospective analysis of all atypical femoral fractures seen in a large California HMO from the years 2007 to 2009. ASBMR 2010 Annual Meeting, Toronto, Canada 2010.
28. Rosenberg Z.S., La Rocca Vieira R., Chan S.S., Babb J., Akyol Y., Rybak L.D., et al. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR 2011, 197:954-960.
29. Feldstein A., Black D., Perrin N., Rosales A.G., Friess D., Boardman D. Incidence and demography of femur fractures with and without atypical features. JBMR 2012, 27(5):977-986.